|Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.|
|Jump to Full Text|
|PMID: 21585347 Owner: NLM Status: MEDLINE|
|BACKGROUND AND PURPOSE: Adipose triglyceride lipase (ATGL) has been identified as a rate-limiting enzyme of mammalian triglyceride catabolism. Deletion of the ATGL gene in mice results in severe lipid accumulation in a variety of tissues including the heart. In the present study we investigated cardiac function in ATGL-deficient mice and the potential therapeutic effects of the PPARα and γ agonists Wy14,643 and rosiglitazone, respectively.
EXPERIMENTAL APPROACH: Hearts isolated from wild-type (WT) mice and ATGL(-/-) mice treated with Wy14,643 (PPARα agonist), rosiglitazone (PPARγ agonist) or vehicle were perfused at a constant flow using the Langendorff technique. Left ventricular (LV) pressure-volume relationships were established, and the response to adrenergic stimulation was determined with noradrenaline (NA).
KEY RESULTS: Hearts from ATGL(-/-) mice generated higher LV end-diastolic pressure and lower LV developed pressure as a function of intracardiac balloon volume compared to those from WT mice. Likewise, passive wall stress was increased and active wall stress decreased in ATGL(-/-) hearts. Contractile and microvascular responses to NA were substantially reduced in ATGL(-/-) hearts. Cardiac contractility was improved by treating ATGL(-/-) mice with the PPARα agonist Wy14,643 but not with the PPARγ agonist rosiglitazone.
CONCLUSIONS AND IMPLICATIONS: Our results indicate that lipid accumulation in mouse hearts caused by ATGL gene deletion severely affects systolic and diastolic function, as well as the response to adrenergic stimulation. The beneficial effects of Wy14,643 suggest that the cardiac phenotype of these mice is partially due to impaired PPARα signalling.
|G Wölkart; A Schrammel; K Dörffel; G Haemmerle; R Zechner; B Mayer|
Related Documents :
|14747237 - Nondipping and its relation to glomerulopathy and hyperfiltration in adolescents with t...
8020517 - Pharmacodynamic effects of iomeprol for injection in experimental animals.
1236607 - The role of the kidney in essential hypertension.
21795567 - Endogenous vascular synthesis of b-type and c-type natriuretic peptides in the rainbow ...
9788987 - Use of intrinsic modes in biology: examples of indicial response of pulmonary blood pre...
20232047 - Comparison of high-frequency oscillation and tracheal gas insufflation versus standard ...
|Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't|
|Title: British journal of pharmacology Volume: 165 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2012 Jan|
|Created Date: 2011-12-19 Completed Date: 2012-04-10 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England|
|Languages: eng Pagination: 380-9 Citation Subset: IM|
|© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.|
|Department of Pharmacology and Toxicology, Karl-Franzens-Universität Graz, Graz, Austria.|
|APA/MLA Format Download EndNote Download BibTex|
Anticholesteremic Agents / pharmacology*
Body Weight / drug effects
Heart / drug effects*, physiopathology
Heart Rate / drug effects
Lipase / deficiency, genetics, physiology*
Myocardium / pathology
Norepinephrine / pharmacology
Organ Size / drug effects
PPAR alpha / agonists*
PPAR gamma / agonists
Pyrimidines / pharmacology*
Thiazolidinediones / pharmacology
Ventricular Dysfunction, Left / pathology, physiopathology
|F 3001-B19//Austrian Science Fund FWF; F 3002-B19//Austrian Science Fund FWF; F 3003-B19//Austrian Science Fund FWF|
|0/Anticholesteremic Agents; 0/PPAR alpha; 0/PPAR gamma; 0/Pyrimidines; 0/Thiazolidinediones; 122320-73-4/rosiglitazone; 51-41-2/Norepinephrine; 86C4MRT55A/pirinixic acid; EC 188.8.131.52/desnutrin protein, mouse; EC 184.108.40.206/Lipase|
Journal ID (nlm-ta): Br J Pharmacol
Journal ID (iso-abbrev): Br. J. Pharmacol
Journal ID (publisher-id): bph
Publisher: Blackwell Publishing Ltd, Oxford, UK
Copyright © 2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell
Received Day: 27 Month: 8 Year: 2010
Revision Received Day: 23 Month: 4 Year: 2012
Accepted Day: 04 Month: 5 Year: 2011
Print publication date: Month: 1 Year: 2012
Volume: 165 Issue: 2
First Page: 380 Last Page: 389
PubMed Id: 21585347
|Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist|
1Department of Pharmacology and Toxicology, Karl-Franzens-Universität GrazGraz, Austria
2Department of Molecular Biosciences, Karl-Franzens-Universität GrazGraz, Austria
|Correspondence: Correspondence Dr Bernd Mayer, Department of Pharmacology and Toxicology, Karl-Franzens-Universität Graz, Universitätsplatz 2, A-8010 Graz, Austria. E-mail: email@example.com
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
Cardiomyopathy is a frequent and significant complication of metabolic disorders such as obesity, insulin resistance and diabetes mellitus. At an early, preclinical stage, cardiomyopathy is characterized by left ventricular (LV) diastolic filling impairments (Schannwell et al., 2002) and evolves over time to both systolic and diastolic dysfunction. Under physiological conditions, cardiomyocytes preferentially utilize long-chain fatty acids (FAs) for ATP generation (Neely et al., 1972). FAs are supplied to the heart via hydrolysis of triglyceride-rich lipoproteins and by uptake of serum albumin-bound FAs originating from adipose tissue stores. In situations of reduced oxygen availability, such as ischaemia or hypertrophy, cardiomyocyte metabolism is shifted towards the utilization of glucose (Wittels and Spann, 1968; Bishop and Altschuld, 1970). In the diabetic heart, the ability of cardiomyocytes to switch from free FA to glucose metabolism is disrupted. Due to the increased supply of circulating FAs and systemic insulin resistance, the diabetic cardiac phenotype is characterized by increased uptake of FAs and depressed glucose metabolism (Feuvray and Darmellah, 2008), resulting in markedly increased triglyceride storage in cardiomyocytes (Sharma et al., 2004). There is convincing evidence that ectopic fat accumulation is toxic to cardiomyocytes and plays an important role in the progress of cardiomyopathy and heart failure (Borradaile and Schaffer, 2005).
Recently, genetic mouse models of cardiac-restricted steatosis have been engineered to unravel the molecular mechanisms of lipotoxicity. As shown by Schaffer and coworkers, myocyte-specific overexpression of the FA transporter protein 1 leads to the accumulation of FAs in the heart and results in a cardiac phenotype similar to that observed in early-stage metabolic cardiomyopathy (Chiu et al., 2005). Murine hearts with an overexpression of glycosyl-phosphatidylinositol-anchored lipoprotein lipase (Yagyu et al., 2003), PPARα (Finck et al., 2002), or long-chain acyl-CoA synthetase A (Chiu et al., 2001) show severe steatosis, systolic dysfunction and hypertrophy, resembling a phenotype observed in end-stage metabolic cardiomyopathies.
Adipose triglyceride lipase (ATGL) has been identified as the key enzyme of triglyceride catabolism, which functions as a monoacyl hydrolase and catalyzes the initial, rate-limiting step of the triacylglycerol lipolysis cascade (Zimmermann et al., 2004). ATGL is predominantly expressed in adipose tissue but is also found to a lesser extent in cardiac muscle, skeletal muscle, testis and other tissues. Systemic deletion of the ATGL gene in mice resulted in massive accumulation of neutral lipids in most tissues (Haemmerle et al., 2006). Similarly, humans with ATGL gene mutations develop neutral lipid storage disease with fat accumulation in multiple tissues (Fischer et al., 2007; Campagna et al., 2008; Hirano et al., 2008). Given that ATGL-deficient mice exhibit increased glucose uptake and utilization, increased glucose tolerance and insulin sensitivity, the metabolic pattern of those animals is opposite to that of diabetic, obese individuals. In cardiac muscle, an age-dependent increase in the number and size of myocyte lipid droplets was observed. In parallel, as shown by two-dimensional echocardiography, cardiac dysfunction progressively developed with age, leading to severe impairments in, and premature death of, ATGL-deficient animals (Haemmerle et al., 2006).
PPARs are members of the nuclear receptor family of ligand-activated transcription factors. They are activated by FAs or FA derivatives and expressed in many cell types including adipocytes, cardiomyocytes, as well as endothelial and vascular smooth muscle cells. Given that lipolysis is necessary to provide FAs as ligands for PPARs, altered PPAR function might contribute to the development of cardiac dysfunction in ATGL-deficient animals. By modulating the expression of a wide variety of target genes, PPARs have pleiotropic effects, including the regulation of metabolism, inflammation, atherogenesis and thrombosis. The PPARα subtype appears to control the expression of genes involved in lipid metabolism, while the PPARγ subtype is a key regulator of glucose homeostasis (Barbier et al., 2002; Marx et al., 2004). In the last decade, genetic and pharmacological approaches have provided abundant evidence for a crucial role of PPARs in the pathogenesis of cardiovascular dysfunction (Schiffrin, 2005; Touyz and Schiffrin, 2006; Zahradka, 2007; Robinson and Grieve, 2009).
In the present study we applied Langendorff perfusion of isolated hearts to investigate the cardiac performance of 9- to 10-week-old ATGL-deficient mice in comparison with age-matched littermates in vitro. Special emphasis was placed on the isovolumic pressure–volume relationship and the cardiac responsiveness to adrenergic stimulation. The potential involvement of defective PPAR signalling was addressed by feeding the mice the PPARα and PPARγ agonists Wy14,643 and rosiglitazone, respectively.
Homozygous ATGL-deficient [ATGL(−/−)] mice of either sex and their corresponding wild-type (WT) littermates were used in this study. In our preliminary study (Haemmerle et al., 2006), the first impairments in cardiac function and lipid accumulation in ATGL(−/−) mice became evident at the age of 6 weeks (comparable with an early diagnosis of neutral lipid storage disease in humans). Therefore, ATGL(−/−) and WT animals (6–7 weeks) were subjected to three different treatment protocols to influence the progression of cardiac dysfunction. The control group received standard mouse chow (4% fat, 20% protein), the PPARα agonist-treated group was fed control diet mixed with 0.1% Wy14,643 (Cayman Chemical, Ann Arbor, MI, USA) for 3 weeks (Crabb et al., 2001), and the PPARγ agonist-treated group was fed control diet mixed with 0.013% rosiglitazone (Cayman Chemical) for 3 weeks (Kanda et al., 2009). This protocol was chosen because ATGL(−/−) mice typically die from cardiac dysfunction at 9–10 weeks. All groups were provided with food and water ad libitum. Food intake was not different between the experimental groups. Animals were housed in approved cages and kept on a regular 12 h dark/light cycle. All animal care and experimental procedures complied with the Austrian law on experimentation with laboratory animals (last amendment, 2004), which is based on the US National Institutes of Health guidelines, and were approved by the local ethical committee[C3] of the Ministry of Science and Education in Austria.
Mice were injected with heparin 1000 U·kg−1 body weight (i.p.) and anaesthetized with urethane 1 g·kg−1. Hearts were rapidly excised and arrested in ice-cold Krebs–Henseleit buffer. After cannulation of the aorta with a 20 gauge needle, retrograde perfusion was established at a constant flow of 20 mL·min−1·g−1 wet weight with a modified Krebs–Henseleit bicarbonate buffer, pH 7.4 (composition in mM: NaCl 118, NaHCO3 25, KH2PO4 1.2, KCl 4.8, MgSO4 1.2, CaCl2 1.25, glucose 11) using the ISO-HEART perfusion system (Hugo Sachs Elektronik, March-Hugstetten, Germany) as previously described (Brunner et al., 2001). The perfusate was filtered through a 5-µm filter before reaching the heart and continuously gassed with carbogen (95% O2, 5% CO2). Heart temperature, measured with a physitemp probe (Physitemp Instruments, Clifton, NJ, USA), was maintained at 37°C throughout the experiments. After removal of the left auricle, a tiny fluid-filled balloon made of a small square of polyethylene film was inserted into the left ventricle and connected to a pressure transducer via a 4F biluminal monitoring catheter (Vygon, Aachen, Germany) (Sutherland et al., 2003). The following cardiac parameters were monitored using the PLUGSYS data acquisition and control set-up for circulatory studies (Hugo Sachs Elektronik) and recorded using a PowerLab system (ADInstruments Ltd, Hastings, UK): LV end-diastolic pressure (LVEDP), peak LV systolic pressure (LVSP), LV developed pressure (LVDevP), maximum rate of rise and fall of LV pressure (+dP/dtmax, –dP/dtmax), heart rate (obtained from the pressure signal using a differentiator and heart rate module, respectively) and coronary perfusion pressure (CPP; via a second pressure transducer attached to the aortic cannula).
Hearts were perfused for 30 min to establish stable baseline conditions. Thereafter, baseline pressure–volume relationships were determined for each heart. The balloon-volume (Vb) was set to the lowest possible volume at which minimal LV pressure tracings (<1 mmHg) could just be recorded. This volume was defined as zero volume. The balloon was then inflated in 5 µL increments using an airtight glass syringe (Hamilton Co., Whittier, CA, USA). LVEDP and LVSP were obtained 1 min after each increment when a new steady state was reached. LV volume was increased up to a value at which maximal LVDevP was reached and a further increase led to a decrease of LVDevP (optimal filling volume; Vmax). LVEDP was then readjusted to 5 mmHg and baseline conditions re-established. Subsequently, noradrenaline (NA; 1 nM–3 µM; non-cumulative dosing) was added via a sideline. At the end of each experiment, hearts were dissected and the different compartments weighed.
LV wall thickness and radius of the left ventricle were derived from the weight of the LV wall plus septum and the balloon volume, respectively, as described previously for rat hearts (Strömer et al., 1997; Wölkart et al., 2000). LV wall stress was then derived from Laplace's law using the relation described by Mirsky (1979).
All data are presented as mean values ± SEM of five experiments per experimental group. In WT hearts, the potency (EC50) of agonists was calculated by fitting individual dose-response curves to a Hill-type model. Concentration-response curves recorded with ATGL(−/−) hearts could not be fitted due to very minor effects of the agonists. ANOVA with post hoc Bonferroni–Dunn test was used for comparison between groups using StatView (Version 5.0) software (SAS Institute Inc., Cary, NC, USA). Significance was assumed at P < 0.05.
At ~10 weeks of age, the body weight of ATGL(−/−) mice was slightly higher than that of WT, but the difference was not statistically significant (20.4 ± 0.9 g and 22.0 ± 0.3 g for untreated WT and ATGL(−/−), respectively). The body weight of ATGL(−/−) mice was significantly decreased after feeding the animals for 3 weeks with the PPARα agonist Wy14,643 (18.7 ± 0.2 g). In contrast, the PPARγ agonist rosiglitazone increased body weight to 24.8 ± 0.3 g. In WT animals, WY14,643 treatment also considerably decreased body weight (14.7 ± 0.3 g), while rosiglitazone was without effect. Triglyceride accumulation in cardiac muscle was already substantially more in untreated ATGL(−/−) mice, demonstrated by substantially higher heart wet weights (183 ± 6 mg) as compared with untreated WT (96 ± 2 mg; P < 0.05). Similar to body weights, heart weights were decreased in Wy14,643-treated (131 ± 4 mg) and increased in rosiglitazone-treated (215 ± 10 mg) ATGL(−/−) animals [P < 0.05 vs. untreated ATGL(−/−)]. A similar but less pronounced pattern was observed in WT animals. Thus, heart-to-body weight ratios were significantly increased in untreated ATGL(−/−) mice as compared with untreated WT (8.3 ± 0.4 and 4.7 ± 0.1, respectively). The decrease in body weight due to PPARα activation was more pronounced in WT (–28%) than in ATGL(−/−) (–18%) animals, while the decrease in heart weight was more pronounced in ATGL(−/−) (–28%) than in WT (–12%) mice. Hence, Wy14,643 treatment decreased the heart-to-body weight ratio in ATGL(−/−) but increased it in WT mice. Rosiglitazone treatment did not affect this parameter in WT or ATGL(−/−) animals (Table 1). Dissection of the hearts revealed that the twofold increase in relative weight was not due to proliferation of specific compartments, indicating whole heart hypertrophy (not shown).
Untreated ATGL(−/−) hearts showed a steeper increase in LVEDP with increasing VB. This pronounced diastolic dysfunction was ameliorated by treating ATGL(−/−) mice with Wy14,643, whereas rosiglitazone had no effect. In contrast, the LVEDP pressure–volume curve was shifted leftwards in WT mice after Wy14,643 treatment (Figure 1A). LVSP was not different between experimental groups at any balloon volume (Figure 1B), but LVDevP was used as indicator of systolic dysfunction rather than LVSP, because evaluating systolic pressure without considering diastolic preload does not reflect the in vivo situation. As shown in Figure 1C, ATGL(−/−) hearts generally exhibited a lower LVDevP than WT. Again, contractility of ATGL(−/−) hearts was improved by Wy14,643 but not by rosiglitazone. Optimal filling volume (Vmax) and maximal LVDevP were significantly higher in WT (42 ± 1 µL, 114 ± 11 mmHg) than in ATGL(−/−) hearts (19 ± 2 µL, 82 ± 9 mmHg). The latter two parameters were improved by Wy14,643 treatment [29 ± 2 µL, 101 ± 5 mmHg; P < 0.05 vs. untreated ATGL(−/−)], but unaffected by rosiglitazone treatment (23 ± 5 µL, 84 ± 5 mmHg). Wy14,643 treatment induced opposite effects in WT animals, that is, it reduced maximal LVDevP (98 ± 6 mmHg) and Vmax (30 ± 4 µL). Importantly, evaluation of absolute pressure values negates differences in heart size and muscle mass. To compensate for differences in heart weights (and consequential wall thickness), wall stress was calculated for each filling volume VB. As shown in Figure 2A, diastolic wall stress was increased in untreated ATGL(−/−) hearts over the whole VB range, suggesting that reduced compliance of cardiac muscle caused by triglyceride accumulation was not effectively compensated for. Diastolic wall stress of ATGL-deficient hearts was not decreased by either of the two PPAR agonists, indicating that these drugs did not significantly affect myocardial compliance. In WT animals, diastolic wall stress was seemingly increased upon Wy14,643 treatment. However, when differences in the size of the ventricular cavities were taken into account by plotting diastolic wall stress versus VB normalized by Vmax, this effect in WT hearts was no longer evident and an improved diastolic function was revealed in Wy14,643-treated ATGL(−/−) hearts (Figure 2B).
Finally, significantly decreased systolic wall stress in ATGL(−/−) hearts at all filling volumes suggests the development of cardiomyopathy in ATGL-deficient mice (Figure 2C). Wy14,643 increased systolic wall stress in WT and ATGL(−/−) hearts at VB > 25 µL, while no effect was observed with rosiglitazone. Again, after normalization of wall stress to differences in the size of the ventricular cavity, the effect of Wy14,643 was not apparent in WT and more pronounced in ATGL-deficient hearts (Figure 2D).
Cardiomyopathic impairments were further analysed by assessing pump function and heart rate in response to adrenergic stimulation. Diastolic pressure was adjusted to 5 mmHg to mimic cardiac preload under physiological conditions. In line with the data shown in Figure 1C, ATGL-deficient hearts showed significantly reduced LVDevP under basal conditions but also exhibited markedly impaired response to NA stimulation as compared with WT littermates (EC50: 13 ± 7 nM; Figure 3A). This loss of the β-adrenoceptor response was not simply confined to reduced inotropy (reduced increase in LVDevP and +dp/dtmax; Figure 3A and B, respectively), but also apparent as reduced lusitropy (reduced increase in –dp/dtmax; Figure 3C), indicating severe systolic and diastolic dysfunction. Importantly, the contractile response to adrenergic stimulation was not improved by treating ATGL(−/−) mice with PPARα or PPARγ agonists. While treating WT mice with the PPARα agonist reduced basal LVDevP (see above), the inotropic response to β-adrenoceptor stimulation was not altered (Δ increase of 79 ± 10 and 70 ± 5 mmHg in untreated and Wy14,643-treated WT animals, respectively). Rosiglitazone had no effect in WT animals.
Basal heart rate was not changed in ATGL deficiency, but the chronotropic response to NA was diminished in untreated ATGL(−/−) hearts (Figure 4A). The response to NA was fully restored by Wy14,643, whereas rosiglitazone had no effect. In WT animals, neither Wy14,643 nor rosiglitazone treatment had any effects on heart rate. Microvascular function of ATGL(−/−) hearts was assessed as NA-induced reduction in CPP, reflecting coronary vasodilatation. As shown in Figure 4B, NA caused pronounced coronary relaxation that was largely abolished in ATGL-deficient hearts. The response to NA was partially restored in hearts obtained from Wy14,643-treated ATGL(−/−) mice, whereas feeding the animals rosiglitazone had no effect (Figure 4B). In WT mice, NA-induced vasodilatation was not affected by either of the two drugs.
Previous work has shown that progressing lipid accumulation and myocardial fibrosis in hearts of ATGL-deficient mice was accompanied by LV hypertrophy and impaired LV systolic function in vivo (Haemmerle et al., 2006). In the present study, we confirmed and extended these observations using an in vitro model of cardiac function that is independent of potential interference by circulating humoural and/or vegetative signals. In addition, we obtained a complete picture of the isovolumic pressure–volume relationship by assessing cardiac function on several points of the Frank–Starling mechanism and showed that PPARα activation improved cardiac contractility.
Diastolic dysfunction was apparent as reduced compliance of the left chamber, rendering ATGL(−/−) hearts more susceptible to even small changes in preload. Importantly, despite a considerably increased wall thickness, calculated passive wall stress was higher in ATGL(−/−) hearts, a condition that is observed in the transition from compensated to decompensated cardiac hypertrophy (Veliotes et al., 2005). The sustained elevation of diastolic wall stress most likely triggered further fibrosis of cardiac muscle, eventually leading to congestive heart failure. Cardiomyopathy of ATGL(−/−) hearts was evident as compromised LV pressure development in response to varying LV filling volumes. The lower developed pressure in ATGL(−/−) hearts was associated with a lower active stress, showing that contractile dysfunction is due to impaired force development of the ventricular muscle, rather than increased muscle mass. Massive fibrosis and apoptosis may partially contribute to this pathology (Haemmerle et al., 2006). Interestingly, the response to inotropic stimulation by NA was also impaired in ATGL-deficient hearts, presumably due to reduced contractile reserve (cf. Figure 1C). Our observations showing a markedly decreased velocity of contraction and relaxation at both baseline condition and after NA stimulation (cf. Figure 3B,C) indicate increased stiffness of the cardiac muscle, most likely reflecting advanced fibrosis. Reduced muscle compliance might also, to some extent, account for the significantly less pronounced increase in heart rate in response to NA, possibly through increased occurrence of arrhythmias. Finally, decreased β-adrenoceptor density and/or receptor-effector coupling might have affected the response to NA in ATGL(−/−) hearts. However, the contractile response to NA was more severely affected by ATGL deficiency than the chronotropic effect (cf. Figures 3A and 4A), suggesting that impaired receptor-effector coupling may account for the reduced chronotropic response, whereas additional mechanisms, for example, fibrosis and/or mitochondrial dysfunction, appear to cause impaired contractility.
An obvious possibility is that heart function in ATGL(−/−) mice is affected by the disordered balance between carbohydrate and FA utilization for energy production. Typically, during development of cardiac hypertrophy and heart failure, myocardial metabolism switches from utilization of long-chain FAs to glucose because of the higher efficiency of glycolysis in terms of ATP generated mol-1 O2 consumed (Bishop and Altschuld, 1970). The effect of catecholamine stimulation on cardiac energy metabolism is less clear. An early study reported about twofold to threefold and threefold to fourfold increases, respectively, in the rates of glucose and triglyceride utilization during adrenergic stimulation in vitro (Williamson, 1964). Others have reported a reduced cardiac glucose uptake after adrenergic stimulation in vivo (Capaldo et al., 1992; Huang et al., 1997). Glucose uptake and utilization are increased in ATGL(−/−) cardiac muscle together with attenuated isoprenaline-stimulated FA mobilization in white adipose tissue (Haemmerle et al., 2006), even though gene expression studies suggest concerted down-regulation of oxidative pathways required for energy production from glucose in ATGL-deficient mice (Pinent et al., 2008). Since our observations of impaired mitochondrial respiration in ATGL-deficient hearts (submitted) indicate that the same applies to cardiac muscle, it is likely that glycolysis alone is not sufficient to provide enough primary energy for an adequate response to adrenergic stimulation.
We recently found that ATGL deficiency leads to severely impaired activation of PPARα and PPARδ target genes in cardiac and skeletal muscle, suggesting that ATGL-catalyzed triglyceride hydrolysis is essential for the supply of FA-derived PPAR ligands in these tissues (unpublished observations). The role of PPARs in cardiac function is not well understood (Zahradka, 2007; Robinson and Grieve, 2009). Activation of PPARγ was reported to inhibit hypertrophy of cardiac myocytes in response to mechanical strain (Yamamoto et al., 2001; Asakawa et al., 2002), whereas activation of PPARα, but not PPARγ, was shown to prevent apoptosis of cardiac myocytes after ischaemia/reperfusion injury (Yeh et al., 2006) and to regulate cardiomyogenesis from embryonic stem cells (Sharifpanah et al., 2008). In a rat coronary artery ligation model, a PPARα agonist attenuated the progression of heart failure by reducing fibrosis and heart weight, while PPARγ activation even exacerbated cardiac dysfunction (Linz et al., 2009). In support of the protective role of PPARα signalling, PPARα-deficient mice were reported to exhibit cardiac contractile dysfunction due to oxidative damage of myosin (Guellich et al., 2007).
In line with previous observations, we observed that PPARα activation of WT animals led to reduced body weight and substantial alterations in heart weight and function (Zungu et al., 2009). In our set-up, reduced contractility after Wy14,643 treatment of WT mice was mainly due to reduced cardiac muscle mass (cf. Figure 2B,D), although additional mechanisms like impaired mitochondrial function (Keller et al., 1993) cannot be excluded. Despite this unfavourable effect in WT animals, Wy14,643 reduced cardiac hypertrophy and improved diastolic and systolic function in ATGL-deficient mice, indicating that PPARα target genes are essential for maintaining normal cardiac function. Our data clearly indicate that this improvement was not simply caused by altered cardiac growth. As stimulation of PPARα triggers the expression of genes involved in lipid metabolism (Marx et al., 2004), treating the mice with Wy14,643 may have led to improved energy supply to the heart through increased rates of FA β-oxidation. Another possible explanation is improved mitochondrial function. Further experiments are needed to address this issue.
The inotropic and chronotropic effects of NA were markedly decreased in ATGL-deficient hearts. Based on the observation that targeted gene deletion of PPARα causes down-regulation of β-adrenoceptors (Loichot et al., 2006), Wy14,643 may have restored the chronotropic response by increasing NA receptor density. However, the explanation for this finding is probably more complex because β-adrenoceptor-mediated contractility was not improved by Wy14,643 in ATGL(−/−) mice and unaltered in WT mice (in terms of Δ increase). The reduced contractile response to NA may reflect attenuated FA mobilization in ATGL-deficient cardiac muscle, as observed previously in white adipose tissue of ATGL(−/−) mice (Haemmerle et al., 2006). Thus, even though the PPARα agonist improved mitochondrial function, glycolysis is apparently not sufficient to supply enough primary energy for a NA-triggered contraction. The observation that the increase in coronary flow in response to NA was reduced in ATGL(−/−) hearts suggests that ATGL deficiency may affect microvascular function. This possibility is currently being investigated in our laboratory.
Rosiglitazone had no cardioprotective effects at all. As the survival rate of PPARγ-deficient mice is extremely low (Duan et al., 2007), the role of PPARγ signalling in the heart is only poorly understood and highly controversial. Animal in vitro studies suggest a cardioprotective role of glitazones in ischaemia/reperfusion injury (Shimabukuro et al., 1996; Khandoudi et al., 2002; Molavi et al., 2006), while recent clinical surveys indicate that the risk of heart failure is even increased by rosiglitazone (Nissen and Wolski, 2007; Home et al., 2009). Notably, in mice overexpressing lipoprotein lipase, another model of lipotoxic cardiomyopathy, PPARγ (but not PPARα) agonists were shown to reduce cardiac lipid levels and markers of cardiomyopathy (Vikramadithyan et al., 2005). However, in that model, the protective effects of PPARγ activation may have been simply due to re-allocation of triglycerides and FAs from the heart to adipose tissue.
In summary, the present study shows that severe cardiac dysfunction due to lipid accumulation in ATGL-deficient mice is improved by activation of PPARα, suggesting that treatment with fibrates may be beneficial in human neutral lipid storage disease.
This work was supported by the Fonds zur Förderung der Wissenschaftlichen Forschung in Austria (SFB F30 Lipotox; R. Zechner, B. Mayer).
|Asakawa M,Takano H,Nagai T,Uozumi H,Hasegawa H,Kubota N,et al. Peroxisome proliferator-activated receptor-γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivoCirculationYear: 20021051240124611889020|
|Barbier O,Torra IP,Duguay Y,Blanquart C,Fruchart JC,Glineur C,et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosisArterioscler Thromb Vasc BiolYear: 20022271772612006382|
|Bishop SP,Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failureAm J PhysiolYear: 19702181531594243400|
|Borradaile NM,Schaffer JE. Lipotoxicity in the heartCurr Hypertens RepYear: 2005741241716386196|
|Brunner F,Andrew P,Wölkart G,Zechner R,Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthaseCirculationYear: 20011043097310211748107|
|Campagna F,Nanni L,Quagliarini F,Pennisi E,Michailidis C,Pierelli F,et al. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathyBiochem Biophys Res CommunYear: 200837784384618952067|
|Capaldo B,Napoli R,Di Marino L,Sacca L. Epinephrine directly antagonizes insulin-mediated activation of glucose uptake and inhibition of free fatty acid release in forearm tissuesMetabolismYear: 199241114611491406302|
|Chiu HC,Kovacs A,Ford DA,Hsu FF,Garcia R,Herrero P,et al. A novel mouse model of lipotoxic cardiomyopathyJ Clin InvestYear: 200110781382211285300|
|Chiu HC,Kovacs A,Blanton RM,Han X,Courtois M,Weinheimer CJ,et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathyCirc ResYear: 20059622523315618539|
|Crabb DW,Pinaire J,Chou WY,Sissom S,Peters JM,Harris RA,et al. Peroxisome proliferator-activated receptors (PPAR) and the mitochondrial aldehyde dehydrogenase (ALDH2) promoter in vitro and in vivoAlcohol Clin Exp ResYear: 20012594595211505017|
|Duan SZ,Ivashchenko CY,Whitesall SE,D'Alecy LG,Duquaine DC,Brosius Iii FC,et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethalityJ Clin InvestYear: 200711781282217304352|
|Feuvray D,Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyteDiabetes MetabYear: 200834Suppl. 139|
|Finck BN,Lehman JJ,Leone TC,Welch MJ,Bennett MJ,Kovacs A,et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitusJ Clin InvestYear: 200210912113011781357|
|Fischer J,Lefèvre C,Morava E,Mussini JM,Laforêt P,Negre-Salvayre A,et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathyNat GenetYear: 200739283017187067|
|Guellich A,Damy T,Lecarpentier Y,Conti M,Claes V,Samuel JL,et al. Role of oxidative stress in cardiac dysfunction of PPARα −/− miceAm J PhysiolYear: 2007293H93H102|
|Haemmerle G,Lass A,Zimmermann R,Gorkiewicz G,Meyer C,Rozman J,et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipaseScienceYear: 200631273473716675698|
|Hirano KI,Ikeda Y,Zaima N,Sakata Y,Matsumiya G. Triglyceride deposit cardiomyovasculopathyN Engl J MedYear: 20083592396239819038890|
|Home PD,Pocock SJ,Beck-Nielsen H,Curtis PS,Gomis R,Hanefeld M,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancetYear: 20093732125213519501900|
|Huang MT,Lee CF,Dobson GP. Epinephrine enhances glycogen turnover and depresses glucose uptake in vivo in rat heartFASEB JYear: 1997119739809337150|
|Kanda T,Brown JD,Orasanu G,Vogel S,Gonzalez FJ,Sartoretto J,et al. PPARγ in the endothelium regulates metabolic responses to high-fat diet in miceJ Clin InvestYear: 200911911012419065047|
|Keller BJ,Bradford BU,Marsman DS,Cattley RC,Popp JA,Bojes HK,et al. The nongenotoxic hepatocarcinogen Wy-14,643 is an uncoupler of oxidative phosphorylation in vivoToxicol Appl PharmacolYear: 199311952588470123|
|Khandoudi N,Delerive P,Berrebi-Bertrand I,Buckingham RE,Staels B,Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injuryDiabetesYear: 2002511507151411978649|
|Linz W,Wohlfart P,Baader M,Breitschopf K,Falk E,Schäfer HL,et al. The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in ratsActa Pharmacol SinYear: 20093093594619503102|
|Loichot C,Jesel L,Tesse A,Tabernero A,Schoonjans K,Roul G,et al. Deletion of peroxisome proliferator-activated receptor-α induces an alteration of cardiac functionsAm J PhysiolYear: 2006291H161H166|
|Marx N,Duez H,Fruchart JC,Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cellsCirc ResYear: 2004941168117815142970|
|Mirsky I. Berne R,Sperelakis N,Geiger SElastic properties of the myocardium: a quantitative approach with physiological and clinical applicationsHandbook of Physiology – The Cardiovascular SystemYear: 1979I (The Heart)Bethesda, MDAmerican Physiological Society497531|
|Molavi B,Chen J,Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPKAm J PhysiolYear: 2006291H687H693|
|Neely JR,Rovetto MJ,Oram JF. Myocardial utilization of carbohydrate and lipidsProg Cardiovasc DisYear: 1972152893294564017|
|Nissen SE,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J MedYear: 20073562457247117517853|
|Pinent M,Hackl H,Burkard TR,Prokesch A,Papak C,Scheideler M,et al. Differential transcriptional modulation of biological processes in adipocyte triglyceride lipase and hormone-sensitive lipase-deficient miceGenomicsYear: 200892263218572100|
|Robinson E,Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and diseasePharmacol TherYear: 200912224626319318113|
|Schannwell CM,Schneppenheim M,Perings S,Plehn G,Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathyCardiologyYear: 200298333912373045|
|Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodelingAm J PhysiolYear: 2005288H1037H1043|
|Sharifpanah F,Wartenberg M,Hannig M,Piper HM,Sauer H. Peroxisome proliferator-activated receptor-α agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanismStem CellsYear: 200826647117951219|
|Sharma S,Adrogue JV,Golfman L,Uray I,Lemm J,Youker K,et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heartFASEB JYear: 2004181692170015522914|
|Shimabukuro M,Higa S,Shinzato T,Nagamine F,Komiya I,Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic ratsMetabolismYear: 199645116811738781306|
|Strömer H,Cittadini A,Szymanska G,Apstein CS,Morgan JP. Validation of different methods to compare cardiac function in isolated hearts of varying sizesAm J PhysiolYear: 1997272H501H5109082860|
|Sutherland FJ,Shattock MJ,Baker KE,Hearse DJ. Mouse isolated perfused heart: characteristics and cautionsClin Exp Pharmacol PhysiolYear: 20033086787814678252|
|Touyz RM,Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implicationsVasc PharmacolYear: 2006451928|
|Veliotes DG,Woodiwiss AJ,Deftereos DA,Gray D,Osadchii O,Norton GR. Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activationHypertensionYear: 20054591492015837836|
|Vikramadithyan RK,Hirata K,Yagyu H,Hu Y,Augustus A,Homma S,et al. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathyJ Pharmacol Exp TherYear: 200531358659315671204|
|Williamson JR. Metabolic effects of epinephrine in the isolated, perfused rat heart. I. Dissociation of the glycogenolytic from the metabolic stimulatory effectJ Biol ChemYear: 19642392721272914216420|
|Wittels B,Spann JF Jr. Defective lipid metabolism in the failing heartJ Clin InvestYear: 196847178717944233124|
|Wölkart G,Strömer H,Brunner F. Calcium handling and role of endothelin-1 in monocrotaline right ventricular hypertrophy of the ratJ Mol CellYear: 20003219952005|
|Yagyu H,Chen G,Yokoyama M,Hirata K,Augustus A,Kako Y,et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathyJ Clin InvestYear: 200311141942612569168|
|Yamamoto K,Ohki R,Lee RT,Ikeda U,Shimada K. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytesCirculationYear: 20011041670167511581147|
|Yeh CH,Chen TP,Lee CH,Wu YC,Lin YM,Lin PJ. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferator-activated receptor α but not γ activatorsShockYear: 20062626227016912651|
|Zahradka P. Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARα) agonist Wy14,643Cardiovasc Drug RevYear: 2007259912217614934|
|Zimmermann R,Strauss JG,Haemmerle G,Schoiswohl G,Birner-Gruenberger R,Riederer M,et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipaseScienceYear: 20043061383138615550674|
|Zungu M,Young ME,Stanley WC,Essop MF. Chronic treatment with the peroxisome proliferator-activated receptor α agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile functionMol Cell BiochemYear: 2009330556219360380|
|ATGL||adipose triglyceride lipase|
|CPP||coronary perfusion pressure|
|LVDevP||left ventricular developed pressure|
|LVEDP||left ventricular end-diastolic pressure|
|LVSP||peak left ventricular systolic pressure|
|Wy14||643, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid|
Effects of the PPAR agonists Wy14,643 and rosiglitazone on body and heart weights of WT and ATGL(−/−) mice
|Body weight (BW; g)||20.4 ± 0.9||14.7 ± 0.3*||21.0 ± 0.4||22.0 ± 0.3||18.7 ± 0.2†||24.8 ± 0.3*, †|
|Heart weight (HW; mg)||96 ± 2||84 ± 2*||105 ± 2*||183 ± 6*||131 ± 4*, †||215 ± 10*, †|
|HW/BW (mg·g−1)||4.7 ± 0.1||5.7 ± 0.1*||5.0 ± 0.2||8.3 ± 0.4*||7.0 ± 0.2*, †||8.7 ± 0.5*|
Data are mean values ± SEM of five hearts.
*P < 0.05 versus untreated WT
†P < 0.05 versus untreated ATGL(−/−) (ANOVA).
Keywords: adipose triglyceride lipase deficiency, lipid accumulation, heart function, PPARα, PPARγ, adrenergic stimulation, noradrenaline.
Previous Document: Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylati...
Next Document: Modulation of presynaptic GABA(A) receptors by endogenous neurosteroids.